MBRX · Moleculin Biotech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $15.89M | $17.73M | $19.49M | $18.97M | $14.42M | $12.76M |
| SG&A | $9.12M | $8.79M | $10.02M | $11.54M | $8.39M | $6.79M |
| Total Operating Expenses | $25.10M | $26.64M | $29.63M | $30.64M | $22.97M | $19.74M |
| D&A | $90.0K | $126.0K | $127.0K | $130.0K | $164.0K | $200.0K |
| Operating Income | ($25.10M) | ($26.64M) | ($29.63M) | ($30.64M) | ($22.97M) | ($19.74M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($33.56M) | ($21.76M) | ($29.77M) | ($29.02M) | ($15.89M) | ($17.36M) |
| EPS - Basic | ($28.42) | ($158.00) | ($376.75) | ($221.25) | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.88M | $4.28M | $23.55M | $43.15M | $70.90M | $15.17M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.51M | $2.03M | $2.50M | $2.10M | $1.36M | $1.13M |
| Current Assets | $9.69M | $5.19M | $26.27M | $45.60M | $72.50M | $17.20M |
| Total Assets | $22.13M | $16.93M | $38.22M | $57.42M | $84.09M | $29.03M |
| Current Liabilities | $6.85M | $5.36M | $6.82M | $4.82M | $3.62M | $2.92M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.12M | $10.95M | $12.14M | $5.23M | $5.10M | $11.27M |
| Stockholders' Equity | $15.01M | $5.98M | $26.07M | $52.19M | $78.99M | $17.76M |
| Retained Earnings | ($206.00M) | ($153.37M) | ($131.60M) | ($101.83M) | ($72.81M) | ($56.92M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.73M) | ($23.86M) | ($24.10M) | ($27.64M) | ($18.95M) | ($17.77M) |
| Investing Cash Flow | $0 | ($13.0K) | ($124.0K) | ($67.0K) | ($19.0K) | ($374.0K) |
| Financing Cash Flow | $27.28M | $4.63M | $4.65M | ($23.0K) | $74.72M | $22.55M |
| CapEx | $0 | $13.0K | $124.0K | $67.0K | $19.0K | $376.0K |
| Free Cash Flow | ($22.73M) | ($23.88M) | ($24.23M) | ($27.71M) | ($18.97M) | ($18.15M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.68 | 1.10 | 0.81 | 0.95 | 1.19 | 1.05 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -151.7% | -128.6% | -77.9% | -50.5% | -18.9% | -59.8% |
| Return on equity | -223.6% | -364.0% | -114.2% | -55.6% | -20.1% | -97.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 |
| Quick ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 |
| Cash ratio | 1.30 | 0.80 | 3.46 | 8.95 | 19.58 | 5.20 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.47 | 2.83 | 1.47 | 1.10 | 1.06 | 1.63 |
| Liabilities / Assets | 0.32 | 0.65 | 0.32 | 0.09 | 0.06 | 0.39 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 5.8% | 10.1% | 3.3% | -33.4% | -16.3% | -12.7% |
| Net income growth (YoY) | -54.2% | 26.9% | -2.6% | -82.6% | 8.4% | -31.4% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 4.8% | 1.4% | 12.6% | -46.1% | -4.5% | -5.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 151.0% | -77.1% | -50.0% | -33.9% | 344.8% | 14.1% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-10.43
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Moleculin Biotech against the 5 most active filers in the same SIC group.